China SXT Pharmaceuticals (SXTC) EBITDA (2017 - 2025)
China SXT Pharmaceuticals (SXTC) EBITDA from Mar 31, 2017 to Mar 31, 2025. The TTM China SXT Pharmaceuticals (SXTC) EBITDA is -$2.60M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
China SXT Pharmaceuticals (SXTC) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year | +12.55% |
| 3 Years | -18.88% |
| 5 Years | +20.82% |
Annual EBITDA change of China SXT Pharmaceuticals (SXTC)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$2.60M | +12.55% |
| 2024 | -$2.31M | -56.90% |
| 2023 | -$5.36M | +10.06% |
| 2022 | -$4.87M | +163.24% |
| 2021 | -$1.85M | +83.17% |
| 2020 | -$1.01M | -151.79% |
| 2019 | $1.95M | +10.80% |
| 2018 | $1.76M | +3.53% |
| 2017 | $1.70M | N/A |
Comparison China SXT Pharmaceuticals (SXTC) five years EBITDA CAGR with competitors
China SXT Pharmaceuticals (SXTC) five years EBITDA CAGR is 7.01%.